Hills RK - Search Results

1

Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12.

Harrison CJ, Hills RK, Moorman AV, Grimwade DJ, Hann I, Webb DK, Wheatley K, de Graaf SS, van den Berg E, Burnett AK, Gibson BE. Harrison CJ, et al. Among authors: hills rk. J Clin Oncol. 2010 Jun 1;28(16):2674-81. doi: 10.1200/JCO.2009.24.8997. Epub 2010 May 3. J Clin Oncol. 2010. PMID: 20439644

2

Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group.

Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM. Tomlinson JW, et al. Among authors: hills rk. Lancet. 2001 Feb 10;357(9254):425-31. doi: 10.1016/s0140-6736(00)04006-x. Lancet. 2001. PMID: 11273062

3

Inappropriate reporting and interpretation of subgroups in the AML-BFM 93 study.

Wheatley K, Hills RK. Wheatley K, et al. Among authors: hills rk. Leukemia. 2001 Nov;15(11):1803-4. doi: 10.1038/sj.leu.2402274. Leukemia. 2001. PMID: 11681429 No abstract available.

4

Evaluating drug treatments for Parkinson's disease: how good are the trials?

Wheatley K, Stowe RL, Clarke CE, Hills RK, Williams AC, Gray R. Wheatley K, et al. Among authors: hills rk. BMJ. 2002 Jun 22;324(7352):1508-11. doi: 10.1136/bmj.324.7352.1508. BMJ. 2002. PMID: 12077043 Free PMC article. Review. No abstract available.

5

Corner cutting compromises clinical trials: the inherent problems with up-front randomisation and a common standard arm.

Hills RK, Richards SM, Wheatley K. Hills RK, et al. Leuk Res. 2003 Dec;27(12):1071-3. doi: 10.1016/s0145-2126(03)00126-7. Leuk Res. 2003. PMID: 12921941 Review.

6

Impact of karyotype on treatment outcome in acute myeloid leukemia.

Grimwade D, Moorman A, Hills R, Wheatley K, Walker H, Harrison G, Harrison Ch, Goldstone A, Burnett A; NCRI Adult Leukaemia Working Party. Grimwade D, et al. Ann Hematol. 2004;83 Suppl 1:S45-8. doi: 10.1007/s00277-004-0849-8. Ann Hematol. 2004. PMID: 15124668 Review.

7

Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy.

Allan JM, Smith AG, Wheatley K, Hills RK, Travis LB, Hill DA, Swirsky DM, Morgan GJ, Wild CP. Allan JM, et al. Among authors: hills rk. Blood. 2004 Dec 15;104(13):3872-7. doi: 10.1182/blood-2004-06-2161. Epub 2004 Aug 31. Blood. 2004. PMID: 15339847 Free article.

8

RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years.

Bowen DT, Frew ME, Hills R, Gale RE, Wheatley K, Groves MJ, Langabeer SE, Kottaridis PD, Moorman AV, Burnett AK, Linch DC. Bowen DT, et al. Blood. 2005 Sep 15;106(6):2113-9. doi: 10.1182/blood-2005-03-0867. Epub 2005 Jun 9. Blood. 2005. PMID: 15951308 Free article.

9

No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

Gale RE, Hills R, Kottaridis PD, Srirangan S, Wheatley K, Burnett AK, Linch DC. Gale RE, et al. Blood. 2005 Nov 15;106(10):3658-65. doi: 10.1182/blood-2005-03-1323. Epub 2005 Aug 2. Blood. 2005. PMID: 16076872 Free article.

10

Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia.

Gale RE, Hills R, Pizzey AR, Kottaridis PD, Swirsky D, Gilkes AF, Nugent E, Mills KI, Wheatley K, Solomon E, Burnett AK, Linch DC, Grimwade D; NCRI Adult Leukaemia Working Party. Gale RE, et al. Blood. 2005 Dec 1;106(12):3768-76. doi: 10.1182/blood-2005-04-1746. Epub 2005 Aug 16. Blood. 2005. PMID: 16105978 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

203 results

Search Page